COMPASS Pathways plc (CMPS)
NASDAQ: CMPS · Real-Time Price · USD
8.44
-0.45 (-5.06%)
At close: Apr 28, 2026, 4:00 PM EDT
8.75
+0.31 (3.67%)
Pre-market: Apr 29, 2026, 7:09 AM EDT
Company Description
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.
The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.
The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.
The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
COMPASS Pathways plc
| Country | United Kingdom |
| Founded | 2020 |
| IPO Date | Sep 18, 2020 |
| Industry | Medical Care Facilities |
| Sector | Healthcare |
| Employees | 156 |
| CEO | Kabir Nath |
Contact Details
Address: 33 Broadwick Street London, W1F 0DQ United Kingdom | |
| Phone | 44 716 6766461 |
| Website | compasspathways.com |
Stock Details
| Ticker Symbol | CMPS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001816590 |
| CUSIP Number | 20451W101 |
| ISIN Number | US20451W1018 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kabir Kumar Nath M.A., M.B.A. | Chief Executive Officer and Director |
| Teri Loxam M.B.A. | Chief Financial Officer |
| Dr. Guy Goodwin | Chief Medical Officer |
| Stephen D. Schultz | Senior Vice President of Investor Relations |
| Lars Christian Wilde | Senior Advisor |
| Dr. Susan C. Stansfield Ph.D. | Advisor |
| Dr. Michael Gold M.D., M.Sc. | Chief Research and Development Officer |
| Lori Englebert M.B.A. | Chief Commercial Officer |
| Dr. Steve Levine M.D. | Chief Patient Officer |
| Benjamin Harber | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2026 | ARS | Filing |
| Apr 15, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 24, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 24, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 24, 2026 | 10-K | Annual Report |
| Mar 24, 2026 | 8-K | Current Report |
| Feb 19, 2026 | 8-K | Current Report |
| Feb 19, 2026 | 424B5 | Filing |
| Feb 17, 2026 | SCHEDULE 13D/A | Filing |
| Feb 17, 2026 | 424B5 | Filing |